TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04653571

Intervention type: OTHER
Intervention: CASPR2 encephalitis
Description: Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.
Study: NCT05732337

Intervention type: DEVICE
Group type: OTHER
Intervention: Poxclin Coolmousse
Description: cooling mousse for application in the skin
Study: NCT05684861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: systemic isotretinoin was given to all 90 patients , dose was prescribed according to weight for 3 months

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ELISA Assays of Serum TWEAK.
Description: : From each subject, 5mL of blood was collected into vacutainers before and after treatment with isotretinoin. The blood samples were centrifuged at 3000g for 10 min at a temperature of 4°C, then . Quantitative determinations for serum TWEAK were achieved using the corresponding commercially available ELISA kit supplied by the AssayMax

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ELISA Assays of Serum TWEAK.
Description: : From each subject, 5mL of blood was collected into vacutainers before and after treatment with isotretinoin. The blood samples were centrifuged at 3000g for 10 min at a temperature of 4°C, then . Quantitative determinations for serum TWEAK were achieved using the corresponding commercially available ELISA kit supplied by the AssayMax
Study: NCT05999071

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coriandrum sativum seeds
Description: Each group consisted of 50 students. In the C. sativum group, dried powdered seeds of C. sativum were administered, while in the control group, starch was provided as a placebo. Both the C. sativum and placebo capsules were identical in shape, color, and outer packaging to maintain the blinding of the participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coriandrum sativum seeds
Description: Each group consisted of 50 students. In the C. sativum group, dried powdered seeds of C. sativum were administered, while in the control group, starch was provided as a placebo. Both the C. sativum and placebo capsules were identical in shape, color, and outer packaging to maintain the blinding of the participants.
Study: NCT04495972

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intestinimonas-capsules
Description: Capsules containing microbiota (Intestinimonas)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-capsules
Description: Placebo capsules are identical to the active treatment
Study: NCT05571475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated competition
Description: During a competition, athletes will typically compete for a reward, against opponents and in the presence of others. This will be replicated in the laboratory.
Study: NCT06322641

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT05691582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRAIL
Description: The subjects experiment GRAIL virtual reality for three days, during which they deal with 4 different activities.~In the first activity subjects are required to ask over the treadmill in a snow environment.~in the second they are required to stand over the moving platform in a simulation of a boat pitch.~in the third they have to walk over a bridge with a slope. in the fourth the subjects are required to try so interact with virtual reality and to ski between snowman.~if it is possible, on the last day a gait analysis is executed
Study: NCT03533153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WJ-MSC cells implantation
Description: Laboratory of Stem Cell of Drum Tower Hospital, Nanjing University Medical School, is able to provide types of Good Manufacture Practice (GMP) level stem cells and stem cell-based medicinal products. Clinical-grade WJ-MSC primary cells are cultured to 4\~ 8 passages, and the surface markers (CD90+, CD105+, CD45-, CD31-, CD117-) are identified by flow cytometry. WJ-MSC cells are trypsinized and resuspended in the wash buffer of CTSTMD PBS (+Ca2+, +Mg2+). Within 2 hours after enzyme digestion, WJ-MSC cells are shipped to coronary care unit (CCU) and injected into the body.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTSTMD PBS without WJ-MSC
Description: For Case-control study only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional drug therapy
Description: All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug therapy
Description: All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
Study: NCT04674813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95266
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Specified dose on specified days
Study: NCT04828018

Intervention type: OTHER
Intervention: Coffee Morning
Description: Coffee mornings (a maximum of n=2) will be held to raise awareness of the project and to promote participant recruitment. These will be held remotely via video conference if Covid-19 restrictions prevent in-person attendance by the researcher.

Intervention type: OTHER
Intervention: Coffee Morning
Description: Coffee mornings (a maximum of n=2) will be held to raise awareness of the project and to promote participant recruitment. These will be held remotely via video conference if Covid-19 restrictions prevent in-person attendance by the researcher.

Intervention type: OTHER
Intervention: Recruitment Leaflets
Description: Recruitment leaflets will be hand-delivered to all In-Pensioner residents at Royal Hospital Chelsea. Leaflets will be delivered internally by Royal Hospital Chelsea internal mail-room

Intervention type: OTHER
Intervention: Recruitment Leaflets
Description: Recruitment leaflets will be hand-delivered to all In-Pensioner residents at Royal Hospital Chelsea. Leaflets will be delivered internally by Royal Hospital Chelsea internal mail-room
Study: NCT04398355

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Liu-Zi-Jue Gongfa
Description: Liu-Zi-Jue Gongfa

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Liu-Zi-Jue Gongfa
Description: Liu-Zi-Jue Gongfa
Study: NCT04872842

Intervention type: OTHER
Intervention: Obervation
Description: This study is an observational study without any intervention

Intervention type: OTHER
Intervention: Obervation
Description: This study is an observational study without any intervention
Study: NCT04913064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: White Button Mushroom Extract
Description: Given PO
Study: NCT06513338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: eculizumab 900mg iv. per week for 4 weeks, then 1200mg every two weeks for week 5 to. week 11
Study: NCT05855044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rosemary oil application
Description: Application of Rosemary oil (10%) to both hands and both feet once a day for 24 weeks
Study: NCT06026527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: 50 mg/kg Magnesium sulphate in 93-95 ml Normal Saline ( making a total of 100 ml solution )will be infused intravenously over 20-30 minutes in the participants allocated to M group starting from the moment of induction of anaesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
Study: NCT05483348

Intervention type: PROCEDURE
Intervention: Endometrial Ablation
Description: Thermal endometrial ablation
Study: NCT04828018

Intervention type: OTHER
Intervention: Consent Form completion
Description: All participants will be asked to complete Consent Forms before engaging in the study. The researcher will be available to answer any questions via phone calls if required.

Intervention type: OTHER
Intervention: Consent Form completion
Description: All participants will be asked to complete Consent Forms before engaging in the study. The researcher will be available to answer any questions via phone calls if required.
Study: NCT05483348

Intervention type: PROCEDURE
Intervention: Endometrial Ablation
Description: Thermal endometrial ablation

Intervention type: PROCEDURE
Intervention: Repeated gynecological procedure
Description: subsequent gynecological procedures such as hysterectomy for any benign indication, D\&C or repeat ablation.
Study: NCT04935502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercises with postural and ergonomic training
Description: Group A will be treated with stretching and strenghtening exercises for 40 minutes along with postural and ergonomic training for 15 minutes session 3 days/week for 4 week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercises
Description: Group B will be given stretching and strengthening exercises for 40 minutes, every alternate day (3 days per week) for 4 weeks.
Study: NCT05702060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial Artery Puncture Method for Coronary Angiography and Intervention
Description: Radial Artery Puncture Method for Coronary Angiography and Intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Artery Puncture Method for Coronary Angiography and Intervention
Description: Radial Artery Puncture Method for Coronary Angiography and Intervention
Study: NCT04828018

Intervention type: OTHER
Intervention: Participant Information Sheet
Description: All participants will receive Information Sheets which they will read in their own rooms (or elsewhere for Key Staff). The researcher will be available to answer any questions via phone calls if required.

Intervention type: OTHER
Intervention: Participant Information Sheet
Description: All participants will receive Information Sheets which they will read in their own rooms (or elsewhere for Key Staff). The researcher will be available to answer any questions via phone calls if required.

Intervention type: OTHER
Intervention: New In-Pensioner Resident Information Pack
Description: New In-Pensioner resident information packs will be distributed by a member of RHC staff as part of their 'arrivals' process and six months after residency at RHC. The researcher will be available to answer any questions via phone calls if required.
Study: NCT05924152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adagrasib
Description: Adagrasib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag + adagrasib
Description: Eltrombopag + adagrasib
Study: NCT06034860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8421
Description: Experimental treatment with MT-8421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8421
Description: Experimental treatment with MT-8421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8421
Description: Experimental treatment with MT-8421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8421
Description: Experimental treatment with MT-8421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
Study: NCT06200181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given by PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given by PO
Study: NCT06137261

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening for heart failure
Description: • Anamnesis and Physical examination: Focus on signs of HF; will be performed by a trained employee.~• ECG: A standard 12-lead ECG will be recorded by a trained employee and will be interpreted by an experienced cardiologist.~• Echocardiography: A standard full echocardiogram will be acquired by a trained employee.~• Blood biomarkers: Venous blood samples will be taken and circulating levels of a broad range of markers related to obesity and/or heart failure will be determined. Also, an extra 10 mL blood sample will be drawn during the same venepuncture to be stored to determine additional biomarkers at a later stage.~• EQ-5D-5L questionnaire: EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which are divided into five degrees of severity, ranging from 'no problems' to 'extreme problems'.
Study: NCT05289167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV over 1 hour on Day +3 and +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
Study: NCT05463328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic assisted pancreaticoduodenectomy
Description: laparoscopic assisted pancreaticoduodenectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pancreaticduodenctomy
Description: Open pancreaticduodenctomy
Study: NCT06371833

Intervention type: DEVICE
Intervention: Shoulder Arthroplasy with PRIMA humeral stem
Description: Data collection of population that underwent a total shoulder arthroplasty with PRIMA humeral stem (anatomic configuration or reverse configuration)
Study: NCT04828018

Intervention type: OTHER
Intervention: Key Staff Interviews
Description: Key Staff interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
Study: NCT06241404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trigger point therapy
Description: patients who have been treated for shoulder tendinopathy by trigger point therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: patients who have been treated for shoulder tendinopathy by exercise therapy
Study: NCT05558033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Exercise
Description: Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Football Training
Description: Routine football trainings
Study: NCT04828018

Intervention type: OTHER
Intervention: In-Pensioner Resident Interviews
Description: In-Pensioner resident interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
Study: NCT05319431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 until disease progression or for a maximum of 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Subjects will receive lenvatinib until disease progression or for a maximum of 24 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: On demand TACE
Study: NCT05119920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 1
Description: Pilocarpine Ophthalmic Topical Cream, Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 2
Description: Pilocarpine Ophthalmic Topical Cream, Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 3
Description: Pilocarpine Ophthalmic Topical Cream, Dose 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Topical Cream
Description: Placebo Ophthalmic Topical Cream
Study: NCT06285682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OliPhenolia®)
Description: Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. Participants will consume three doses within the entire study, one dose per visit, separated by a ≥3 day wash out period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OliPhenolia®)
Description: Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. Participants will consume three doses within the entire study, one dose per visit, separated by a ≥3 day wash out period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OliPhenolia®)
Description: Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. Participants will consume three doses within the entire study, one dose per visit, separated by a ≥3 day wash out period.
Study: NCT05880095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unrestricted Mediterranean diet
Description: Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy-reduced Mediterranean diet
Description: Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with time-restricted eating
Description: Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
Study: NCT04828018

Intervention type: OTHER
Intervention: ICECAP-A Quality of Life Questionnaire
Description: New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.

Intervention type: OTHER
Intervention: ICECAP-A Quality of Life Questionnaire
Description: New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.

Intervention type: OTHER
Intervention: WHOQOL-BREF Quality of Life Questionnaire
Description: New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.

Intervention type: OTHER
Intervention: WHOQOL-BREF Quality of Life Questionnaire
Description: New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.